Abstract
HMG-CoA (3-hydroxy-3-methyl glutaryl coenzyme A) reductase inhibitors are associated with muscle injury. Chronic kidney disease (CKD) carries a high risk for the development of statin-induced myopathy. Statin therapy decreases the absolute risk of cardiovascular diseases in patients with CKD; however, rhabdomyolysis increases with deteriorating kidney function.